echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Feed Industry News > FDA plans to ban the use of two kinds of livestock and poultry (12.12)

    FDA plans to ban the use of two kinds of livestock and poultry (12.12)

    • Last Update: 2003-03-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The U.S Food and Drug Administration (FDA) announced Friday that it plans to ban farmers who raise poultry in the United States from using two antibiotics As a result of the use of the drug, bacteria have increased their resistance to the drug, which is the main cause of diseases after people eat meat According to the FDA, when people consume meat with antibiotic resistant bacteria or come into contact with contaminated meat, such bacteria will enter the human body Soon, the U.S Food and Drug Administration will issue a formal notice banning the use of the two drugs At present, more and more attention has been paid to the fact that large-scale use of antibiotics in poultry may affect the therapeutic effect of patients using antibiotics The two drugs, Baytril and Sara Flox, according to the FDA, plan to withdraw their use approvals because they have recently been found to be unsafe Both of them are influenza quinolones, which are the most effective antibiotics for the treatment of human infectious diseases They can also treat diseases caused by food Fluoroquinolones has been used in human body since 1986 It is a common drug in the prescription of gastrointestinal diseases The drug has also been used by poultry breeders, resulting in a dramatic increase in bacterial resistance to the antibiotic, the FDA said In this case, the FDA believes that only the use of such drugs is prohibited The FDA doesn't think it's wrong to use the drug, but admits that the use of the drug in poultry does significantly increase bacterial resistance In the United States, Campylobacter is the most common food borne disease, with an annual incidence rate of about 2 million According to the Centers for Disease Control and prevention of the United States, in 1998, about 13.6% of people with Campylobacter disease were resistant to fluoroquinolones, but last year, the proportion had increased to 17.6% But Bayer, Baytril's manufacturer, disagrees with the FDA, calling for a thorough and comprehensive investigation into the drug resistance of antibiotics used to treat animals It also stated that there was no increase in drug resistance in chickens Another poultry regulator said the rise in human resistance was not all due to the drug's role Long before the FDA approved the use of the drug in poultry and livestock, officials from consumer groups and some health agencies questioned the potential for increased bacterial resistance They said the FDA should not have agreed to use the drug from the beginning The FDA defended its approval of the drug's use, saying it was acting in the right way The FDA's recommendations will not affect the use of the drug in cattle  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.